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Abstract Despite improvement of prognosis, older age
remains a negative prognostic factor in acute promyelocytic
leukemia (APL). Reports on disease characteristics and out-
come of older patients are conflicting. We therefore ana-
lyzed 91 newly diagnosed APL patients aged 60 years or
older (30 % of 305 adults with APL) registered by the
German AML Cooperative Group (AMLCG) since 1994;
68 patients (75 %) were treated in studies, 23 (25 %) were
non-eligible, and 31 % had high-risk APL. Fifty-six patients
received induction therapy with all-trans retinoic acid and
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TAD (6-thioguanine, cytarabine, daunorubicin), and consol-
idation and maintenance therapy. Treatment intensification
with a second induction cycle (high dose cytarabine, mitox-
antrone; HAM) was optional (n014). Twelve patients were
randomized to another therapy not considered in this report.
The early death rate was 48 % in non-eligible and 19 % in
study patients. With the AMLCG regimen, 7-year overall,
event-free and relapse-free survival (RFS) and cumulative
incidence of relapse were 45 %, 40 %, 48 %, and 24 %,
respectively. In patients treated with TAD–HAM induction,
7-year RFS was superior (83 %; p00.006) compared to
TAD only, and no relapse was observed. In our registered
elderly patients, we see a high rate of non-eligibility for
treatment in studies and of high-risk APL. In patients who
can undergo a curative approach, intensified chemotherapy
is highly effective, but is restricted to a selection of patients.
Therefore, new less toxic treatment approaches with broader
applicability are needed. Elderly patients might be a partic-
ular target group for concepts with arsenic trioxide.
Keywords Acute promyelocytic leukemia . Elderly
patients . Early death . Treatment
Introduction
With current treatment strategies, 70 % to 80 % of patients
with acute promyelocytic leukemia (APL) included in mul-
ticenter trials can be cured. Despite improvement of prog-
nosis over the last two decades, older age remains a
prominent negative prognostic factor [1].
Older APL patients seem to be as sensitive to specific
APL therapy as younger individuals. It is generally assumed
that in elderly APL patients a higher vulnerability to
treatment-related toxicity causes an increased rate of
treatment-related mortality. These observations led to rec-
ommendations to reduce the intensity of the chemotherapy
combined with all-trans retinoic acid (ATRA) in older APL
patients or to use less toxic strategies based on arsenic
trioxide [1–4].
In larger studies, the incidence of APL patients aged over
60 and 70 years ranged from 9 % to 24 % and 3 % to 7 %,
respectively, giving the impression that APL is relatively
rare in older age [5–10]. Few publications have specifically
reported the outcome in larger series of older patients. These
studies included on average 15 % high-risk patients accord-
ing to the Sanz Score suggesting that older APL patients
present more frequently with low-risk features [2, 7, 11, 12].
A population-based study from the USA reported an
early death (ED) rate of 24 % in APL patients aged 55 years
or older. In the Swedish Adult Leukemia Registry, the ED
rate of 105 unselected APL patients of all age groups was
29 %, and of patients over 60 years, it was 50 % [13, 14].
This is much higher than reported in treatment studies. It can
therefore be assumed that a considerable proportion of el-
derly patients is not included in clinical trials.
We report here the characteristics and outcome of 91 APL
patients over 60 years representing 30 % of all APL patients
registered by the German AML Cooperative Group
(AMLCG) from 1994 to 2011. A relatively high rate
(31 %) was assigned to the high-risk group and 25 % were
not eligible for inclusion in the studies. The treatment con-
sisted of ATRA and chemotherapy. The design allowed
individual intensification of the therapy.
Design and methods
Eligibility criteria and recruitment of patients
From December 1994 to November 2011, 305 adult patients
with newly diagnosed APL have been registered by 60
centers participating in the studies of the AMLCG. From
1994 to November 2005, the patients were uniformly treated
with the regimen of the German AMLCG [15]. Since De-
cember 2005, the patients were randomly assigned to the
previous AMLCG protocol or to the strategy of the Spanish
PETHEMA (German Clinical Trials Register, numbers
DRKS00004313 and DRKS00004314). Eligibility criteria
were newly diagnosed APL, cytogenetic or molecular con-
firmation of the diagnosis, age over 16 years without upper
age limit, and written informed consent. Exclusion criteria
were other antecedent or concomitant malignancy; cardiac
failure NYHA III and IV; chronic renal failure with serum
creatinine ≥2 mg/100 ml; severe liver disease; pneumonia
with hypoxemia, sepsis, or other severe infection; uncon-
trolled life-threatening bleeding; and frailty. In accordance
with the Declaration of Helsinki, the protocols were ap-
proved by the Research Ethics Board of each participating
center. The confirmation of the diagnosis APL by morpho-
logical, cytogenetic, and/or molecular characterization of
the leukemic cells in central laboratories was mandatory.
All data of the patients were registered at the Institute of
Biostatistics and Clinical Research, University of Münster,
Germany.
Ninety-one patients (30 %) (Fig. 1) were ≥60 years and
33 patients (11 %) ≥70 years. Of these, 68 patients (75 %)
were eligible for inclusion in the study. The reasons for non-
eligibility in the 23 remaining patients (25 %) were death
before therapy (n05), reduced performance status/comor-
bidity according to the exclusion criteria (n011), and con-
comitant malignancy (n07). Fifty-six patients were treated
with the AMLCG regimen, 47 patients in the first and nine
patients in the second protocol. The 12 patients treated
according to the PETHEMA strategy were not considered
in this report to assure homogeneity of therapy.
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Design of the AMLCG regimen for elderly patients
Patients over 60 years received an age-adapted version of
the AMLCG protocol with less intensive chemotherapy as
the younger patients [15]. The induction therapy started with
all-trans retinoic acid (ATRA) 45 mg/m2/day and simulta-
neous chemotherapy with TAD. The administration of the
second induction cycle, HAM with high-dose cytarabine
(ara-C), was at the discretion of the treating physician. Its
application was mainly influenced by the assessment of the
physician, whether the patient could tolerate the toxicity of
two induction cycles. The start of HAM was scheduled at
day21 after the start of TAD and could be delayed in
dependence on the individual tolerance of the first cycle.
ATRA was continued until complete hematological remis-
sion (CR) or for a maximum of 90 days independent of the
number of induction cycles. [TAD—6-thioguanine (6-TG)
100 mg/m2 orally every 12 h, days 3–9, ara-C 100 mg/m2 by
continuous intravenous (i.v.) infusion, days 1–2, thereafter
100 mg/m2 as i.v. infusion every 12 h, days 3–8, daunoru-
bicin (DNR) 60 mg/m2 i.v. infusion, days 3–5; HAM—ara-
C 1 g/m2 (instead of 3 g/m2 as in younger patients) i.v.
infusion every 12 h, days 1–3, mitoxantrone 10 mg/m2 i.v.
infusion, days 3–5].
Supportive treatment for coagulopathy, oral antimicrobial
prophylaxis as well as diagnosis and management of the
APL differentiation syndrome were performed according to
international standards [15].
Consolidation therapy with one cycle TAD started 2 to
4 weeks after CR followed by 3-year monthly maintenance
therapy consisting of ara-C 200 mg/m2/days.c. over 5 days
combined with either DNR 45 mg/m2, days 3 and 4 (course
1), or 6-TG 200 mg/m2/day over 5 days (course 2 and 4), or
cyclophosphamide 1 g/m2 i.v., day 3 (course 3). The
sequence was restarted with DNR (course 5). After a cumu-
lative DNR dose of 540 mg/m2, DNR was replaced by 6-
TG. Dose adaptations were performed as described else-
where [15].
Bone marrow aspiration for morphological evaluation
and molecular monitoring by RT–PCR was mandatory after
induction and consolidation, and was recommended every
3 months during maintenance therapy.
Definitions and endpoints
CR was defined according to the National Cancer Institute
criteria [16] and molecular remission as negative nested RT–
PCR for PML–RARA (sensitivity 10−4). Molecular relapse had
to be confirmed by nested RT–PCR in two marrow samples
taken 2 to 4 weeks apart. In eligible patients, EDwas defined as
death between start of therapy and achievement of CR, and in
non-eligible patients as death within 30 days after diagnosis
[13]. Overall survival (OS) was calculated from the start of
induction therapy until death for eligible patients, and from
diagnosis until death in non-eligible patients, event-free surviv-
al (EFS) from the start of therapy until non-achievement of
remission or relapse or death, and relapse-free survival (RFS)
from the date of CR until molecular or hematological relapse or
death in remission, whichever occurred first. The cumulative
incidence of relapse (CIR) was calculated from the date of CR
until molecular or hematological relapse taking into account
death in CR as competing risk.
Statistical analysis
Comparison of the CR rates and categorical variables was
evaluated by Fisher’s exact test. Continuous variables were
compared using the Mann–Whitney U test. All p values
reported are two-sided. Distributions of time-to-event vari-
ables were estimated by the Kaplan–Meier method [17].
Comparisons were based on the log-rank test. Cumulative
incidences were calculated according to Cooley et al. [18].
Differences in the rates of CIR were calculated with the
Gray test [19]. Analysis of the reported data was in Novem-
ber 2011. All calculations were done using SAS software




The initial characteristics of all 91 registered patients were
separated according to non-eligibility (n023), treatment
within the study (n068), and treatment with the AMLCG















Included in the PETHEMA-arm
of AMLCG 2005 Study
n=56
Treated with AMLCG-strategy 
in 1994 and 2005 Studies
Fig. 1 Flow chart separating according to age, eligibility, and treat-
ment of the 305 APL patients registered by the German AMLCG.
Ninety-one patients (30 %) were ≥60 years; of these, 68 (75 %) were
treated in studies and 23 (25 %) were non-eligible
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confirmed. The rate of high-risk patients according to the
Sanz Score was 31 %. Sixty percent of patients had the
BCR3 transcript (short variant), and 50 % had additional
cytogenetic abnormalities in combination with the translo-
cation t(15;17). Besides a higher rate of non-eligible females
(p00.002), there was no statistical difference of the initial
patient characteristics between the four groups.
In the 56 patients treated with the AMLCG regimen, ATRA
was started simultaneously with TAD in 30 patients and before
TAD in 26 patients (median 6 days, range 1 to 12). Fourteen
patients (25 %) received the second induction cycle (HAM). In
five of these patients, the CR criteria were reached before the
start of HAM. The median time between start of TAD until
HAM was 35 days (range 22 to 55). Retrospectively analyzed,
the relevant characteristics of patients treated with TAD–HAM
showed no significant difference to patients alive after TAD and
treated with TAD induction only. Notably, there was no statis-
tical difference of the duration of ATRA therapy in both groups
(p00.4), of the percentage of patients below and above 70 years
(p00.6), and of patients with high versus low/intermediate risk
according to the Sanz Score (p00.5) (Table 2).
Response to induction therapy
The results of induction therapy of all patients and separated
according to initial WBC count and age below and above
70 years are shown in Table 3. Hematological CR was
achieved in 82 % of patients. The median time to CR was
37 days (range 22 to 55) in patients with TAD only, and
70 days (24 to 89) in patients treated with TAD–HAM. No
resistance against therapy was observed. ED occurred in
18 % of patients between days 2 and 19 after start of induc-
tion therapy. No patient died from ED after TAD–HAM. The
ED rate was higher in the high WBC group (p00.009) and in
patients over 70 years (p00.06). Causes of ED were bleeding,
multiorgan failure, and sepsis (Table 4). Three patients died in
CR on days 33, 50, and 73, respectively, after start of induc-
tion therapy from cardiac failure (n01) or for unknown rea-
sons (n02). Molecular remission was documented in 22 of 33
(67 %) patients after induction.
The APL differentiation syndrome was diagnosed in
25 % of patients between days 2 and 29 after the start of
induction therapy. Other adverse effects WHO grade ≥3
were fever or infection in 43 % of patients (45 % in patients
treated with TAD only and 36 % in patients with TAD/
HAM); cardiac failure was observed in 16 %, diarrhea in
13 %, hepatotoxicity in 11 %, and hemorrhage in 7 % of
patients.
Post-remission outcome
Consolidation therapy with TAD was administered in 36 of
the 43 (84 %) living patients and omitted in seven cases
(16 %) due to severe side effects during induction. Two
patients died after consolidation from sepsis in neutropenia
on days 74 and 77, respectively, after start of induction therapy
(Table 4). After consolidation therapy, 31 of 33 (94 %) tested
patients were in molecular remission. Maintenance therapy
Table 2 Characteristics of patients with TAD–HAM vs. TAD induction therapy
Induction cycles TAD–HAM TAD only p value
Patients alive after TAD induction course n014 n032
Median age (range) 66 (61–70) 66 (60–80) 0.6
Gender, ratio (male/female) 2.5 1.1 0.3
WBC count median (range) ×109/L 1.4 (0.4–26.1) 2.4 (0.4–71.8) 0.6
Initial WBC count less than 10×109/L: n, (%) 12 (86) 23 (72) 0.5
Initial WBC count 10×109/L or more: n, (%) 2 (14) 9 (28)
Low riska: n, (%) 8 (57 %) 7 (22 %) 0.07
Intermediate riska: n, (%) 4 (29 %) 16 (50 %)
High riska: n, (%) 2 (14 %) 9 (28 %)
Fever/infection WHO grade 3 or more during course 1: n, (%) 5 (36) 15 (47) 0.5
APL differentiation syndrome (course 1): n, (%) 4 (29) 9 (28) 1.0
Days of ATRA; median (range) 51 (22–90) 38 (20–89) 0.4
Patients younger than 70 years (n034) 11 (32 %) 23 (68 %) 0.6
Patients 70 years or older (n012) 3 (25 %) 9 (75 %)
RFS at 7 years 83 [60;100] 35 [16;54] 0.01
CIR at 7 years 0 34 [20;56] 0.03
WBC count white blood cell count, ATRA all-trans retinoic acid, RFS relapse-free survival, CIR cumulative incidence of relapse
a According to Sanz Risk Score
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was started in 71 % of the living patients (29 of 41),
corresponding to 57 % of the TAD–HAM group and to
65 % of the TAD-only group. It was prematurely terminated
between course 1 and 8 in eight cases (20 %) resulting in
completion of maintenance therapy in 50 % of the TAD–
HAM patients and of 44 % of the TAD-only group.
The median follow-up of the 56 patients treated with the
AMLCG regimen was 7.4 years (1 day to 14.6 years). The 7-
year OS was 45 %, EFS 40 %, RFS 48 %, and CIR 24 %
(Table 3, Fig. 2a, b). Ten relapses occurred. All were hemato-
logical relapses of the bone marrow, in two cases preceded by
molecular relapse. No extramedullary relapse was observed. Of
the 29 total deaths, 10 were due to ED, eight due to first or later
relapse, and 11 patients died in CR. Approximately 50 % of
these deaths in CR were probably therapy-related after induc-
tion, consolidation, and during maintenance therapy, and 50 %
died for other reasons during long-term follow-up (Table 4).
Secondary malignancies were observed in six patients (11 %)
(MDS/secondary AML, n03; non-Hodgkin lymphoma, n01;
GIST, n01; colon carcinoma, n01).
Patients with initial WBC counts ≥10×109/L had a sig-
nificantly inferior outcome concerning OS (p00.002), EFS
(p00.0001), RFS (p00.008), and CIR (p00.004). There
was no significant difference between RFS and CIR of
intermediate and low-risk patients according to the Sanz
Score, respectively [11]. Advanced age ≥70 years was asso-
ciated with a shorter OS as compared to age <70 years (p0
0.048). However, when CR was reached, RFS (p00.8) and
CIR (p00.7) did not differ significantly (Table 3, Fig. 2c–f).
Patients who achieved CR after TAD–HAM had a supe-
rior RFS of 83 % (p00.006) and a better CIR (p00.002), as
no relapse was observed in the TAD–HAM group. For
comparison, in the patients treated with TAD induction only,
the RFS was 35 % and the CIR 34 %. Separated according
to initial WBC counts less than or ≥10×109/L, the rates of
RFS and CIR after TAD induction only were 41 % and
19 %, and 22 % and 67 %, respectively (Fig. 2g, h).
Outcome of the non-eligible patients
The 7-year OS of all 91 registered patients was 41 %
[53;29]. Figure 3 separately shows the OS of eligible (n0
68) and non-eligible (n023) patients. In the non-eligible
group, 48 % (n011) of patients died from ED after a median
time of 9 days (range 2–22) as compared to 19 % ED (n0
13) in the 68 study patients (AMLCG or PETHEMA regi-
mens). Antecedent malignancy (n03) and severe pneumo-
nia requiring mechanical ventilation (n01) were reasons for
exclusion of the four non-eligible patients, who survived
longer than 2 years (Fig. 3). These patients received ATRA
and anthracycline-based therapy outside of the study.
Discussion
The data of the present study show that APL is curable
in a considerable proportion of older patients. The pres-
ent study differs from other reports. We found a consid-
erable rate of older patients (25 %) not eligible for
treatment with standard therapy leading to a positive
selection of study patients and a high rate of patients
with high-risk profile (31 %). Less intensive chemother-
apy during induction was associated with an increased
relapse rate and reduced RFS.
Concerning the high rate of non-eligibility of 25 %, it may
be assumed that the true exclusion rate is even higher because
the registration of non-eligible patients was not performed
with the same stringency at all centers [20]. Remarkably,












n056 n038 n018 n038 n018
n (%) n (%) n (%) n (%) n (%)
CR (%) 46 (82) 35 (92) 11 (61) 34 (89) 12 (67)
Early death (%) 10 (18) 3 (8) 7 (39) 0.009 4 (11) 6 (33) 0.06
OS at 7 years (%) 45 [30;61] 55 [37;73] 26 [5;47] 0.002 54 [37;72] 25 [1;75] 0.048
EFS at 7 years (%) 40 [26;54] 53 [35;70] 15 [0;33] 0.0001 46 [49;63] 28 [4;52] 0.1
RFS at 7 years (%) 48 [32;65] 57 [38;76] 24 [0;52] 0.008 51 [32;70] 42 [9;75] 0.8
CIR at 7 years (%) 24 [14;41] 13 [05;32] 58 [34;98] 0.004 26 [14;48] 19 [5;65] 0.7
WBC white blood cell count, CR complete hematological remission, OS overall survival, EFS event-free survival, RFS relapse-free survival, CIR
cumulative incidence of relapse
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besides an unexplained higher rate of exclusions in females
than in men, there was no significant difference in the initial
patients’ characteristics between the eligible and non-eligible
patients. In particular, there was no difference in the distribu-
tion of risk groups (Table 1). These data suggest that the non-
eligibility of older patients is probably more determined by
multimorbidity and performance status than by APL-specific
factors. The median survival of the non-eligible patients was
only 2 months, and longer survival was restricted to patients
who unexpectedly improved and were later able to receive
standard-like therapy (Fig. 3).
Forty-eight percent of the non-eligible and 19 % of the 68
patients included in the studies died within 22 days after
diagnosis or after start of therapy. This corresponds to an ED
rate of 26 % of all 91 registered patients. The results of the
56 patients, treated with the AMLCG regimen, show an
increased rate of ED in patients with high WBC counts
(p00.009) and with advanced age (Table 3). For











71; f M 3 v 46.0 2 Multiorgan failure
78; f M 3 v 23.0 3 Multiorgan failure
66; m M 3 v 26.9 5 Bleeding (cerebral)
75; f M 3 15.6 7 Bleeding (pulmonal)
83; m M 3 v 15.4 9 Multiorgan failure
83; m M 3 1.0 12 Infection/sepsis
67; m M 3 v 42.1 15 Infection/sepsis
67; m M 3 v 19.0 15 Bleeding (pulmonal)
82; f M 3 12.0 17 Infection/sepsis
68; m M 3 59.0 19 Multiorgan failure
Death in CR after induction or consolidation n05
80; m M 3 v 1.2 33 Cardiac failure
68; f M 3 v 7.8 50 Not reported, in CR of APL
65; f M 3 v 45 73 Multiorgan failure
64; m M 3 0.4 74 Sepsis
61;f M 3 9.4 77 Sepsis
Death in CR during follow-up n06
65; f M 3 22.0 237 Sepsis in cytopenia after
maintenance
75; m M 3 v 0.9 888 Not reported, in CR of APL
62; m M3 0.6 1637 After MDS and allo. transpl.,
in CR of APL
75; f M 3 0.5 1896 Not reported, in CR of APL
75; m M 3 2.5 2263 Poor performance status, in
CR of APL
69; m M 3 v 19.3 3359 Colon carcinoma, in CR of
APL
Death after relapse n08
75; f M 3 1.7 351 First relapse
60; f M 3 1.2 788 Third relapse
66; f M3 v 71.8 895 Second relapse
64; m M 3 v 41.0 1037 Second relapse
65; f M 3 v 7.1 1418 Second relapse
61; m M 3 30.8 1638 First relapse
71; f M 3 25.1 1821 Second relapse
70; m M 3 0.5 2140 Second relapse and GIST
WBC count white blood cell count, CR complete remission, MDS myelodysplastic syndrome, allo. transpl. allogeneic transplantation, GIST
gastrointestinal stromal tumor
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comparison, in our 142 APL patients younger than 60 years
and treated with the AMLCG-type chemotherapy, the ED
rate was only 8 % [15]. Causes of ED differed with age.
Besides fatal hemorrhage in 30 %, multiorgan failure and
sepsis caused 70 % of the ED in the elderly patients, which
is possibly a consequence of the reduced tolerance of the
chemotherapy. In our younger patients, bleeding was the
cause of death in 64 % of ED and sepsis in only 9 % [15].
These data show that the high ED rate is a great and
unresolved problem with high impact on the outcome of
older patients, as also reported by others [13, 14, 20–22].
The 7-year OS of patients treated with the AMLCG
regimen was 45 % and of all registered patients 41 %,
compared to more than 80 % in younger APL patients [3, 9,
15, 23]. The percentage of 30 % registered elderly patients and
their outcome are comparable to recently published data of a
population-based study from the USA. This analysis reported
the registration of 32 % APL patients older than 60 years
among 1,397 APL cases and a 5-year survival rate below
40% in cases diagnosed between the years 2000 and 2008 [24].
The OS of our study patients was significantly shorter in
patients with high WBC counts and advanced age over
70 years (Fig. 2a, c, e). It was much better, however, com-
pared to older patients with other AML subtypes, who
reached cure in about 15 % [25]. Twenty-four percent of
the patients, who had achieved remission, died in CR. In
approximately 50 % of these patients, the chemotherapy-
related toxicity had an influence on the fatal outcome
(Table 4). Twenty percent of patients died in first or later
relapse. These data demonstrate that three main reasons had an
impact on the fatal outcome: the high ED rate, the
chemotherapy-related toxic effects followed by death in CR,
and the high relapse rate. Similar observations were made by
others [2, 3, 7, 20, 21]. But due to differences of the risk
profile of the included patients and of the treatment regimens,
a direct comparison with other studies is not possible.
The results further show that our older patients who
received intensified chemotherapy with HAM benefited
from this approach, reflecting the results of younger patients
(Fig. 2g, h) [15, 26]. An inferior outcome after only one
induction course (TAD) was seen in low-risk/intermediate
and high-risk patients. These patients received a relatively
low cumulative daunorubicin dose of 360 mg/m2 during
induction and consolidation therapy and no high dose ara-
C and no mitoxantrone. The beneficial prognostic influence
of higher doses of chemotherapy combined with ATRA is
also supported by other reports. The Spanish PETHEMA
reported an excellent outcome in older APL patients with
ATRA and a relatively high cumulative dose of anthracy-
clines (68 to 100 mg/m2 idarubicin and 50 mg/m2 mitoxan-
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Fig. 3 OS of study patients compared to non-eligible patients. Bold
line: OS of all patients treated in studies (n068); dotted line: OS of the
non-eligible patients (n023) (p00.002). The non-eligible patients who
survived longer than 2 years had received standard-like therapy
Fig. 2 a OS of all patients treated with the AMLCG regimen (n056).
Median observation time was 7.4 years. The OS was 45 % at 7 years. b
CIR of all patients treated with the AMLCG regimen who entered
remission (n046). CIR of these patients was 24 % at 7 years. c OS of
the 56 patients treated with the AMLCG regimen separated according
to WBC counts less than and ≥10×109/L. OS was significantly supe-
rior in patients with WBC counts <10×109/L (p00.002). Bold line: OS
of patients with initial WBC counts <10×109/L (n038) was 55 % at
7 years; dotted line: OS of patients with WBC counts ≥10×109/L (n0
18) was 26 % at 7 years. d CIR of the 46 patients who entered
remission after treatment with the AMLCG regimen separated accord-
ing to WBC counts less than and ≥10×109/L. CIR was significantly
superior in patients with WBC counts <10×109/L (p00.004). Bold
line: CIR of patients with initial WBC counts <10×109/L (n035)
was 13 % at 7 years; dotted line: CIR of patients with WBC counts
≥10×109/L (n011) was 58 % at 7 years. e OS of the 56 patients treated
with the AMLCG regimen separated according to age 60 to 69 and
≥70 years. OS was significantly shorter in advanced age (p00.048).
Bold line: OS of patients 60 to 69 years of age (n038) was 54 % at
7 years; dotted line: OS of patients >70 years (n018) was 25 % at
7 years. f CIR of the 46 patients who entered remission after treatment
with the AMLCG regimen separated according to age 60 to 69 and
≥70 years. There was no significant difference of CIR in both groups
(p00.7). Bold line: CIR of patients 60 to 69 years of age (n034) was
26 % at 7 years; dotted line: CIR of patients ≥70 years (n012) was
19 % at 7 years. g RFS of patients treated with TAD–HAM or with
only one induction course, TAD. In the group with TAD alone, the
patients were additionally separated according to initial WBC counts
less than and ≥10×109/L. The outcome was significantly improved
after TAD–HAM (p00.006) as compared to TAD induction alone.
Bold line: RFS of patients with initial WBC counts <10×109/L (n0
23) and treatment with only one induction cycle (TAD) was 41 % at
7 years; dotted line: RFS of patients with WBC counts ≥10×109/L (n0
9) and treatment with only one induction cycle was 22 % at 7 years;
broken line: RFS of the patients treated with TAD–HAM induction (n0
14) was 83 % at 7 years. h CIR of patients treated with the AMLCG
regimen separated according to double induction therapy with TAD–
HAM and with only one induction course, TAD. In the group with
TAD alone, the patients were additionally separated according to initial
WBC counts less than and ≥10×109/L. There was a significantly lower
CIR after TAD–HAM (p00.002) as compared to TAD induction alone.
Bold line: CIR of patients with initial WBC counts <10×109/L (n023)
and treatment with only one induction cycle (TAD) was 19 % at
7 years; dotted line: CIR of patients with WBC counts ≥10×109/L
(n09) and treatment with only one induction cycle was 67 % at 7 years;
broken line: CIR of the patients treated with TAD–HAM induction
(n014) was 0 % at 7 years
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Italian studies, the reduction of poly-chemotherapy cycles
had beneficial effects on survival due to reduction of toxic-
ity [2, 22]. In younger Italian low-risk/intermediate risk
patients treated with the PETHEMA-type concept, the ex-
panded application of ATRA during anthracycline-based
consolidation therapy improved the outcome despite omis-
sion of the non-anthracycline part of chemotherapy [23]. In
elderly APL patients, it would be of particular interest in
how far the amount of chemotherapy could be reduced when
prolonged ATRA was administered. Currently, no general
recommendation can be given which dose or modification
of chemotherapy and ATRA is optimal.
Our observations suggest that a considerable proportion
of older APL patients with poor prognosis are excluded
from treatment in studies and indicate that the results of
clinical trials do not reflect the true outcome of the entire
older APL population. In elderly patients who can undergo a
curative approach, intensified chemotherapy is highly effec-
tive, but remains restricted to a selection of patients. There-
fore, new less toxic but efficient treatment approaches with
broader applicability are needed in elderly APL. As sug-
gested by recent reports, elderly patients may represent a
particular target group to replace chemotherapy by arsenic
trioxide, which should be addressed in future trials [28–31].
Furthermore, molecular markers might contribute to better
adapted treatment in genetically determined APL risk
groups also in the elderly patients [32].
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Appendix
The following institutions and clinicians participated in the
study: University Hospital, Aachen (T. Ittel); Municipal
Hospital Augsburg (C. Schmid); Municipal Hospital, Bad
Saarow (H. Fuß); Municipal Hospital Neukölln, Berlin (A.
Mayr, A. Grüneisen); University Hospitals Charité, Berlin
(R. Arnold, B. Dörken, G. Maschmeyer, A. Trittin); University
Hospital Benjamin Franklin, Berlin (M. Notter, E. Thiel); Uni-
versity Hospital Robert Rössle, Berlin (W.D. Ludwig, D.
Schöndube); Municipal Hospital, Bielefeld (A. J. Weh, A.
Zumsprekel); Knappschaft Hospital, Bochum (C. Teschendorf,
M. Stechstor); Knappschaft Hospital, Bottrop (G. Trenn);
Diakonissen Hospital, Bremen (G. Kessler, Th. Wolff); Munic-
ipal Hospital St. Jürgenstraße, Bremen (B. Hertenstein, H.
Thomssen, A. Peyn);MunicipalMedical Center, Braunschweig
(B. Wörmann); St. Johannes Hospital, Dortmund (H. Pielken,
H. Hindahl); University Hospital, Düsseldorf (A. Heyll);
Municipal Hospital, Düren (M. Flaßhove, J. Karow); St.
Johannes Hospital, Duisburg (C. Aul, C. Giagounidis); St.
Antonius Hospital, Eschweiler (R. Fuchs, F. Schlegel);
Tumorklinik, Essen (S. Seeber); Evangelian Hospital,
Krankenhaus Essen-Werden, (Ch. Tirier); St. Joseph-
Hospital, Gelsenkirchen (G. Meckenstock, G. Giagounidis);
University Hospital, Göttingen (D. Haase, F. Griesinger);
Municipal Hospital, Gütersloh (C. Gropp, R. Depenbusch);
Municipal Hospital, Hagen (H. Eimermacher, W.
Lindemann); Municipal Hospital Martha-Maria, Halle (W.
Schütte, U. Haak); General Hospital Altona, Hamburg (D.
Braumann); Evangelian Hospital, Hamm (L. Balleisen);
Municipal Hospital Siloah, Hannover (H. Kirchner); District
Hospital, Herford (J.G. Lange, U. Schmitz-Hübner); Marien
Hospital, Herne (B. Schultheis); Municipal Hospital,
Idar-Oberstein (A. Fauser); University Hospital, Jena (H.-J.
Fricke); Municipal Hospital, Kassel (M. Wolf, B. Ritter);
Westpfalz Hospital, Kaiserslautern (H. Link); University
Hospital II, Kiel (M. Kneba, H.A. Horst); University Hos-
pital, Köln (M. Hallek, P. Staib, K.A. Kreuzer); Municipal
Hospital, Köln (A. Dormann); Municipal Hospital, Krefeld
(Th. Frieling, M. Planker); Hospital Lippe-Lemgo, Lemgo
(F. Hartmann, H. Middeke); Dreifaltigkeit-Hospital, Lippstadt
( K.A. Jost); Municipal Hospital, Leverkusen (N. Niederle);
University Hospital, Lübeck (Th. Wagner); Municipal Hospi-
tal South-Lübeck, Lübeck (S. Fetscher, J. Schmielau); Munic-
ipal Hospital, Ludwigshafen (M. Uppenkamp,M. Hoffmann);
University Hospital, Mannheim (R. Hehlmann, E. Lengfelder,
W.-K. Hofmann); St. Walburga Hospital, Meschede (M.
Schwonzen); Maria-Hilf-Hospital, Mönchengladbach (D.
Graeven, D. Kohl); Municipal Hospital Harlaching, München
(M. Hentrich, X. Schiel); University Hospital Innenstadt,
München (B. Emmerich, R. Dengler, B. Schlag); Univer-
sity Hospital Großhadern, München (W. Hiddemann, K.
Spiekermann, J. Braess); Municipal Hospital Neuperlach,
München (K. Nibler, D. Fleckenstein); Hospital Barmherzige
Brüder, Regensburg (M. Schenk); University Hospital, Münster
(T. Büchner, W. E. Berdel, U. Krug, C. Müller-Tidow); Munic-
ipal Hospital, Osnabrück (J. Hartlapp, T. Hegge, R. Peceny);
Paracelsus Hospital, Osnabrück (O. Koch, G. Innig); Municipal
Medical Center, Passau (Th. Südhoff, Th. Wagner); University
Hospital, Regensburg (A. Reichle, R. Andreesen); Municipal
Hospital, Siegen (W. Gassmann, T. Gaska); Ammerland-Klinik,
Westerstede (D. Kohl); Dr. Horst Schmitt Hospital, Wiesbaden
(N. Frickhofen, H-G. Fuhr); Heinrich Braun Hospital, Zwickau
(U. Kreibich, G. Schott, S. Sommer, W. Zschille).
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